The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.

@article{RiveroJuarez2013TheIE,
  title={The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.},
  author={Antonio Rivero-Juarez and Luis Fernando L{\'o}pez-Cort{\'e}s and {\'A}ngela Camacho and Antonio Caruz and Almudena Torres-Cornejo and Loreto Mart{\'i}nez-Due{\~n}as and Rosa Ruiz-Valderas and Juli{\'a}n Torre-Cisneros and Alicia Gutierrez-Valencia and Antonio Rivero},
  journal={AIDS},
  year={2013},
  volume={27 12},
  pages={1941-7}
}
OBJECTIVE To evaluate the IL28B effect on hepatitis C virus (HCV) decline during first weeks of treatment according to HCV-1 subtypes. METHODS Patients coinfected with HIV/HCV genotype 1 and naive to peginterferon-alpha-2a and ribavirin (Peg-IFN-alpha-2a/RBV) were included. Plasma HCV-RNA was measured at baseline, and then at weeks 1, 2, and 4. HCV-1 subtype (1a or 1b) was determined. HCV viral decline was analyzed according to HCV-1 subtype between baseline and week 1, week 2 and week 4 of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS